112 related articles for article (PubMed ID: 31776034)
21. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
22. Discovery of selective BPTF bromodomain inhibitors by screening and structure-based optimization.
Xiong L; Mao X; Guo Y; Zhou Y; Chen M; Chen P; Yang S; Li L
Biochem Biophys Res Commun; 2021 Mar; 545():125-131. PubMed ID: 33548625
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
Chen Z; Zhang H; Liu S; Xie Y; Jiang H; Lu W; Xu H; Yue L; Zhang Y; Ding H; Zheng M; Yu K; Chen K; Jiang H; Luo C
Medchemcomm; 2017 Jun; 8(6):1322-1331. PubMed ID: 30108844
[TBL] [Abstract][Full Text] [Related]
25. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.
Lu T; Hu JC; Lu WC; Han J; Ding H; Jiang H; Zhang YY; Yue LY; Chen SJ; Jiang HL; Chen KX; Chai HF; Luo C
Acta Pharmacol Sin; 2018 Sep; 39(9):1544-1552. PubMed ID: 29795359
[TBL] [Abstract][Full Text] [Related]
26. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
27. Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer.
Fang Z; Zhang L; Liao Q; Wang Y; Yu F; Feng M; Xiang X; Xiong J
J Exp Clin Cancer Res; 2017 Jan; 36(1):17. PubMed ID: 28114950
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells.
Guan Y; Guan X; An H; Baihetiya A; Wang W; Shao W; Yang H; Wang Y
Am J Transl Res; 2019; 11(5):3226-3237. PubMed ID: 31217891
[TBL] [Abstract][Full Text] [Related]
30. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
31. Discovery of BAZ2A bromodomain ligands.
Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
33. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.
Gupta SD; Swapanthi PS; Bhagya D; Federicci F; Mazaira GI; Galigniana MD; Subrahmanyam CVS; Gowrishankar NL; Raghavendra NM
Anticancer Agents Med Chem; 2020; 20(3):369-385. PubMed ID: 31713499
[TBL] [Abstract][Full Text] [Related]
34. Development of small molecule inhibitors of BRPF1 and TRIM24 bromodomains.
Palmer WS
Drug Discov Today Technol; 2016 Mar; 19():65-71. PubMed ID: 27769360
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
Chen H; Xu F; Liang X; Xu BB; Yang ZL; He XL; Huang BY; Yuan M
Bioorg Med Chem Lett; 2015 Jan; 25(2):285-7. PubMed ID: 25488843
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
